1. CD137 + T-Cells: Protagonists of the Immunotherapy Revolution.Cancers (Basel). 2021 Jan 26;13(3):456. 2.An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int JMol Sci. 2019 Apr; 20(8): 1822. 3.Immunotherapy targeting 4-1BB...
4-1BB作为共刺激因子结构域(co-stimulatory domains,CD)被广泛用于CAR-T细胞治疗。 CAR-T(嵌合抗原受体T)细胞,具有针对癌细胞的定向特异性,是一种很有前景的治疗癌症的方法。目前全球已有6款CAR-T产品上市。4-1BB广泛应用于CAR-T产品的结构设计,诺华的Kymriah的共刺激结构域是4-1BB。作为CAR-T细胞的胞内共刺...
Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011 Jul;8(4):281-4. Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol. 2015 Jun 8;5:117. Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-...
1. CD137 + T-Cells: Protagonists of the Immunotherapy Revolution.Cancers (Basel). 2021 Jan 26;13(3):456. 2.An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int JMol Sci. 2019 Apr; 20(8): 1822. 3.Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, ...
4. Activation of CD8 T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. DOI:10.1158/2326-6066.CIR-19-0743. 达科为官网:www.bio-city.net Email: tech_immuno@dakewe.net 全国免费热线:400 819 7199 北京达科为:010-64...
Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011 Jul;8(4):281-4. Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol. 2015 Jun 8;5:117. Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-...
[3] Ying Wang, et al. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Cytotherapy, 2021.[4] Cheuk, Mufti, and Guinn. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Therapy,...
Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Cytotherapy, 2021. [4] Cheuk, Mufti, and Guinn. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Therapy, 2004...
而与“去刹车”的作用原理相反,科学家目前还在探索开发基于共刺激分子的免疫疗法,希望通过“加油门”来增强T细胞对癌细胞的攻击力,4-1BB就是其中一种重要的共刺激分子。 目前 ,4-1BB已被广泛应用于CAR-T产品的结构设计,现有研究也支持4-1BB靶向抗体在肿瘤免疫中的治疗潜力。
[3]Engineered T cells: The promise and challenges of cancer immunotherapy[J]. Nature reviews. Cancer, 2016, 16(9):566-581. [4] Chester C , Sanmamed M F , Wang J , et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies[J]. Blood, 2017:...